The study duration for each subject would be up to 20 days. There is a possible screening period of up to 7 days and a treatment period of 13 days. After obtaining Informed consent, subjects will be screened for inclusion and exclusion criteria, clinical and demographic data, Physical examination, collection of anthropometric measurements, vital Signs, lab investigations (Hematology, Biochemistry, Lipid profile, Glucose, Blood Insulin and Urine analysis), UPT will be performed for female subjects before and after the study. Once all the eligibility criteria are met, participant will be enrolled to the study. Subjects will be housed at least 10-12 hr prior to dosing till 4 hr after dosing on each visit. The night meal will be served to the participants as per the Institutional standards at least 10-12hrs before the test/reference dose served as per treatment chart. Diet will be served under the supervision of delegated study team member to the subjects. Subjects will be evaluated for well-being and checked out from the facility. Concomitant medication and adverse events will be reported on each visit days during study conduct including check in and checkout days. The study end points includes-Primary endpoint Such as Measurement of Blood glucose levels at all time points including pre-dose samples. Secondary endpoint includes measurement of serum Insulin levels on all dosing days.